Company: APO
Filing Date: 2025-08-08
Form Type: 424B5
Source: 0001193125-25-177032
Chunk: 72

Company: Apollo Global Management, Inc.
Filing Date: 2025-08-08
Form: 424B5
Chunk 72
---
              |   533 |
| Noncurrent liabilities                              |     |              | 5,220 |
| Due to related parties, excluding non-guarantor     
 subsidiaries                                        |     |              |   123 |
| Redeemable preferred stock                          |     |              |   554 |
| Noncontrolling interests                            |     |              |     6 |

|                                          |     | Year ended   
 December 31, 
 2022         |       |
|:-----------------------------------------|:----|:-------------|------:|
| Summarized Statement of Operations       |     |              |       |
| Revenues                                 |     |              | 2,842 |
| Net income                               |     |              |   913 |
| Net income attributable to obligor group |     |              |   855 |

The following are transactions of the obligor group with non-guarantorsubsidiaries for the year ended December 31, 2022 (in millions):

| Due from non-guarantor subsidiaries |     | 185 |
| Due to non-guarantor subsidiaries   |     | 151 |
| Intercompany revenue                |     | 764 |
| Intercompany other income (loss)    |     | 770 |

7

RISK FACTORS

Any investment in our securities involves a high degree of risk. You should carefully consider the specific risks described in the 2022 10-K, and the various risk factors incorporated by reference in the applicable prospectus supplement, together with all the other information contained in the applicable prospectus supplement or incorporated by
reference in this prospectus and the applicable prospectus supplement. See “Incorporation of Documents by Reference” and “Where You Can Find More Information.” These risk factors may be amended, supplemented or superseded from
time to time in the applicable prospectus supplement and by other reports we file with the SEC in the future. If any of these risks were to occur, the Company’s business, financial condition or operating results could be harmed, which may
reduce our ability to pay dividends on or redeem shares of our capital stock. In addition, the trading price of our securities may be adversely affected. You may lose all or part of your investment.

8

USE OF PROCEEDS

We intend to use the net proceeds we receive from the sale of the securities offered by this prospectus for general corporate purposes, unless
we specify otherwise in the applicable prospectus supplement. General corporate purposes may include additions to working capital, capital